Intrinsic Therapeutics completed patient enrollment in the company's randomized superiority clinical trial of the Barricaid anular closure device.
The controlled trial includes 550 patients worldwide and it aims to investigate reherniation, reoperation, economic impact and risk-factors associated with clinical outcomes following lumbar discectomy.
"This randomized trial is a massive undertaking and has already contributed significantly in confirming an elevated risk of reoperation in a subset of discectomy patients," said Steven Garfin, MD, chairman of orthopedic surgery at University of California San Diego.
Intrinsic Therapeutics is a medical device company focused on treating lumbar disc herniations.
More articles on devices:
6 points on FDA panel physicians …and their payments from device companies
What is Stryker responsible for in the OtisMed settlement? 5 things to know
What happens when data links device company payments with physician decisions?